ACADIA Pharmaceuticals (NASDAQ: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders. We have a pipeline of product candidates led by NUPLAZID™ (pimavanserin), which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis.
All of ACADIA's product candidates emanate from internal discoveries. We believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. We have assembled a strong team of industry-experienced executives to lead the development and commercialization of our product candidates.back to top